COLD-fx studied in children.

CV Technologies, Edmonton, AB, Canada, has unveiled positive safety results for a pilot clinical trial, marking the first step in developing a children's formulation of COLD-fx, which is a top selling cold and flu remedy in Canada.

The randomized, double-blind, placebo-controlled study measured the safety and tolerability of COLD-fx for treatment of cold and flu in children. Acute 3-day doses were well tolerated with no serious adverse events versus the placebo group.

For the study--conducted in the winter of 2005-2006--75 children between the ages of 3 and 12 were recruited in Edmonton. Of those, 46 developed an upper respiratory tract infection and were randomly assigned to receive 3-day treatment with either a placebo or COLD-fx (2 weight-based dosage levels). Approved by Health Canada and the University of Alberta Ethics Committee, the trial was conducted in collaboration with pediatric researchers in the Faculty of Medicine at the University of Alberta, Edmonton. The findings were presented at two major scientific conferences, including the Annual Symposium on Complementary Health Care in Exeter, U.K.